利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

28 条记录 (耗时 0.047 秒)

    1,3-dihydro-2H-indol-2-one derivative
    1.
    发明授权
    1,3-dihydro-2H-indol-2-one derivative 失效
    1,3-二氢-2H-吲哚-2-酮衍生物

    公开(公告)号：US07528124B2

    公开(公告)日：2009-05-05

    申请号：US10569833

    申请日：2004-08-27

    申请人： Toshihito Kumagai ,  Takeshi Kuwada ,  Tsuyoshi Shibata ,  Masato Hayashi ,  Yuri Fujisawa ,  Yoshinori Sekiguchi

    发明人： Toshihito Kumagai ,  Takeshi Kuwada ,  Tsuyoshi Shibata ,  Masato Hayashi ,  Yuri Fujisawa ,  Yoshinori Sekiguchi

    IPC分类号： A61K31/404 ,  C07D209/04 ,  C07D403/04

    CPC分类号： C07D403/04

    摘要： A 1,3-dihydro-2H-indol-2-one derivative expressed by Formula 1 (wherein R1 is a halogen atom, a C1 to C4 alkyl group, etc., and R2 is a hydrogen atom, a halogen atom, etc., or R2 is in the 6-position of the indol-2-one and R1 and R2 join together to form a C3 to C6 alkylene group, R3 is a halogen atom, a hydroxyl group, etc., and R4 is a hydrogen atom, a halogen atom, a C1 to C4 alkyl group, etc., or R4 is in the 3-position of the phenyl and R3 and R4 join together to form a methylenedioxy group, R5 is a hydrogen atom or a fluorine atom, R6 is an ethylamino group, a dimethylamino group, etc., R7 is a C1 to C4 alkoxy group, and R8 is a C1 to C4 alkoxy group), or a pharmaceutically acceptable salt of this derivative. This is a novel compound that has antagonistic activity against an aruginine-vasopressin V1b receptor.

    摘要翻译： 由式1表示的1,3-二氢-2H-吲哚-2-酮衍生物（其中，R 1为卤素原子，C 1〜C 4烷基等，R 2为氢原子，卤素原子等） ，或R2为吲哚-2-酮的6-位，R 1和R 2连接在一起形成C 3〜C 6亚烷基，R 3为卤素原子，羟基等，R 4为氢原子 卤素原子，C 1〜C 4烷基等，或者R 4在苯基的3-位，R3和R4连接在一起形成亚甲二氧基，R5是氢原子或氟原子，R6是 乙基氨基，二甲基氨基等，R7为C1〜C4烷氧基，R8为C1〜C4烷氧基）或该衍生物的药学上可接受的盐。 这是一种新的化合物，具有对抗葡萄糖酸加压素V1b受体的拮抗作用。

    1,3-Dihydro-2h-indol-2-one derivative
    2.
    发明申请
    1,3-Dihydro-2h-indol-2-one derivative 失效
    1,3-二氢-2H-吲哚-2-酮衍生物

    公开(公告)号：US20060276449A1

    公开(公告)日：2006-12-07

    申请号：US10569833

    申请日：2004-08-27

    申请人： Toshihito Kumagai ,  Takeshi Kuwada ,  Tsuyoshi Shibata ,  Masato Hayashi ,  Yuri Fujisawa ,  Yoshinori Sekiguchi

    发明人： Toshihito Kumagai ,  Takeshi Kuwada ,  Tsuyoshi Shibata ,  Masato Hayashi ,  Yuri Fujisawa ,  Yoshinori Sekiguchi

    IPC分类号： A61K31/404 ,  C07D403/14 ,  C07D403/04

    CPC分类号： C07D403/04

    摘要： A 1,3-dihydro-2H-indol-2-one derivative expressed by Formula 1 (wherein R1 is a halogen atom, a C1 to C4 alkyl group, etc., and R2 is a hydrogen atom, a halogen atom, etc., or R2 is in the 6-position of the indol-2-one and R1 and R2 join together to form a C3 to C6 alkylene group, R3 is a halogen atom, a hydroxyl group, etc., and R4 is a hydrogen atom, a halogen atom, a C1 to C4 alkyl group, etc., or R4 is in the 3-position of the phenyl and R3 and R4 join together to form a methylenedioxy group, R5 is a hydrogen atom or a fluorine atom, R6 is an ethylamino group, a dimethylamino group, etc., R7 is a C1 to C4 alkoxy group, and R8 is a C1 to C4 alkoxy group), or a pharmaceutically acceptable salt of this derivative. This is a novel compound that has antagonistic activity against an aruginine-vasopressin V1b receptor.

    摘要翻译： 由式1表示的1,3-二氢-2H-吲哚-2-酮衍生物（其中R 1是卤素原子，C 1至C 1烷基， 4个烷基等，R 2是氢原子，卤原子等，或R 2 2位在6位的 吲哚-2-酮和R 1和R 2连接在一起以形成C 6 -C 6亚烷基， 亚烷基，R 3是卤素原子，羟基等，R 4是氢原子，卤原子，C 1， / SUB→C 4烷基等，或R 4在苯基的3位和R 3和R 3 连接在一起形成亚甲二氧基，R 5是氢原子或氟原子，R 6是乙氨基，二甲基氨基 基团等，R 7是C 1-4烷氧基的C 1至C 8，并且R 8是 C 1至C 4烷氧基），或该衍生物的药学上可接受的盐。 这是一种新的化合物，具有对抗葡萄糖酸加压素V1b受体的拮抗作用。

    Cyclic amine compound
    7.
    发明授权
    Cyclic amine compound 失效
    环胺化合物

    公开(公告)号：US07601734B2

    公开(公告)日：2009-10-13

    申请号：US11578169

    申请日：2005-04-08

    申请人： Toshihito Kumagai ,  Toshio Nakamura ,  Yuri Amada ,  Yoshinori Sekiguchi

    发明人： Toshihito Kumagai ,  Toshio Nakamura ,  Yuri Amada ,  Yoshinori Sekiguchi

    IPC分类号： A61K31/44 ,  A61P25/18 ,  A61P25/24

    CPC分类号： C07D491/048 ,  C07D471/04 ,  C07D495/04

    摘要： An object of the present invention is to provide a cyclic amine compound which has a potent inhibitory effect on the binding of α2C-adrenoceptor and is useful in preventing and treating disorders attributable to α2C-adrenoceptor.The above-described object is solved by the following cyclic amine compound, etc., wherein X is O, S, SO, SO2 or NR2, etc.; R1 is a hydrogen atom, a cyano group, a carboxyl group, a C2-C13 alkoxycarbonyl group, a carbamoyl group, etc.; Ar1 and Ar2 are the same or different and each represent an aryl or heteroaryl group which may be substituted by 1 to 3 substituents and so on; ring B is a benzene ring may be substituted by 1 to 3 substituents and so on; n is an integer from 1 to 10; and p and q are the same or different and each represent an integer of 1 or 2.

    摘要翻译： 本发明的目的是提供对α2C-肾上腺素能受体的结合具有强效抑制作用的环胺化合物，可用于预防和治疗归因于α2C-肾上腺素受体的病症。 上述目的通过以下环胺化合物等来解决，其中X是O，S，SO，SO 2或NR 2等; R1是氢原子，氰基，羧基，C2-C13烷氧基羰基，氨基甲酰基等; Ar 1和Ar 2相同或不同，各自表示可被1〜3个取代基等取代的芳基或杂芳基; 环B为苯环可被1〜3个取代基取代等; n是1至10的整数; p和q相同或不同，各自表示1或2的整数。

    Cyclic Amine Compound
    8.
    发明申请
    Cyclic Amine Compound 失效
    环胺化合物

    公开(公告)号：US20070244145A1

    公开(公告)日：2007-10-18

    申请号：US11578169

    申请日：2005-04-08

    申请人： Toshihito Kumagai ,  Toshio Nakamura ,  Yuri Amada ,  Yoshinori Sekiguchi

    发明人： Toshihito Kumagai ,  Toshio Nakamura ,  Yuri Amada ,  Yoshinori Sekiguchi

    IPC分类号： A61K31/44 ,  A61P25/18 ,  A61P25/24

    CPC分类号： C07D491/048 ,  C07D471/04 ,  C07D495/04

    摘要： An object of the present invention is to provide a cyclic amine compound which has a potent inhibitory effect on the binding of α2C-adrenoceptor and is useful in preventing and treating disorders attributable to α2C-adrenoceptor. The above-described object is solved by the following cyclic amine compound, etc., wherein X is O, S, SO, SO2 or NR2, etc.; R1 is a hydrogen atom, a cyano group, a carboxyl group, a C2-C13 alkoxycarbonyl group, a carbamoyl group, etc.; Ar1 and Ar2 are the same or different and each represent an aryl or heteroaryl group which may be substituted by 1 to 3 substituents and so on; ring B is a benzene ring may be substituted by 1 to 3 substituents and so on; n is an integer from 1 to 10; and p and q are the same or different and each represent an integer of 1 or 2.

    摘要翻译： 本发明的目的是提供对α2C-肾上腺素能受体的结合具有强效抑制作用的环胺化合物，可用于预防和治疗归因于α2C-肾上腺素受体的病症。 上述目的通过以下环胺化合物等来解决，其中X是O，S，SO，SO 2或NR 2等; R 1是氢原子，氰基，羧基，C 1 -C 13烷氧基羰基，氨基甲酰基等 。 Ar 1和Ar 2相同或不同，各自表示可被1至3个取代基等取代的芳基或杂芳基; 环B为苯环可被1〜3个取代基取代等; n是1至10的整数; p和q相同或不同，各自表示1或2的整数。

    1-NAPHTHYL ALKYLPIPERIDINE DERIVATIVE
    9.
    发明申请
    1-NAPHTHYL ALKYLPIPERIDINE DERIVATIVE 审中-公开

    公开(公告)号：US20100081825A1

    公开(公告)日：2010-04-01

    申请号：US12444275

    申请日：2007-10-05

    申请人： Yoshinori Sekiguchi ,  Kosuke Kanuma ,  Kazunari Sakagami ,  Masato Hayashi ,  Shuhei Kashiwa ,  Katsunori Omodera

    发明人： Yoshinori Sekiguchi ,  Kosuke Kanuma ,  Kazunari Sakagami ,  Masato Hayashi ,  Shuhei Kashiwa ,  Katsunori Omodera

    IPC分类号： C07D211/58 ,  C07D401/10

    CPC分类号： C07D405/12 ,  C07D211/58 ,  C07D401/10 ,  C07D401/12 ,  C07D405/10 ,  C07D409/12

    摘要： Disclosed is a pharmaceutical composition comprising a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, which has an antagonistic activity on a melanin-concentrating hormone receptor. The pharmaceutical composition is useful, due to its antagonistic activity on a MCH receptor, for the prevention or treatment of a disease such as depression, anxiety disorders (e.g., generalized anxiety disorder, post traumatic stress disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder), attention deficit disorder, mania, manic-depressive disorder, schizophrenia, mood disorders, stress, sleep disorder, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, a cardiovascular diseases, hypertension, dyslipidemia, cardiac infarction, movement disorder (e.g., Parkinson's disease, epilepsy, convulsion, tremor), drug abuse and drug addiction.

    摘要翻译： 公开了一种药物组合物，其包含式（I）表示的化合物或其药学上可接受的盐作为活性成分，其对黑色素浓缩激素受体具有拮抗作用。 由于其对MCH受体的拮抗活性，药物组合物可用于预防或治疗诸如抑郁症，焦虑症（例如广泛性焦虑症，创伤后应激障碍，恐慌症，强迫症， 社会焦虑障碍），注意力缺陷障碍，躁狂症，躁狂抑郁障碍，精神分裂症，情绪障碍，压力，睡眠障碍，发作，记忆障碍，认知障碍，痴呆，遗忘症，del妄，肥胖，进食障碍，食欲障碍， 糖尿病，心血管疾病，高血压，血脂异常，心肌梗死，运动障碍（如帕金森病，癫痫，惊厥，震颤），药物滥用和药物成瘾。